Session

Investigator studies in IBD II (Posters)

EARLY ANTI-TNF RESULTS IN HIGHER SUSTAINED STEROID FREE REMISSION RATES IN NEWLY DIAGNOSED PAEDIATRIC CROHN’S DISEASE PATIENTS
EARLY ANTI-TNF RESULTS IN HIGHER SUSTAINED STEROID FREE REMISSION RATES IN NEWLY DIAGNOSED PAEDIATRIC CROHN’S DISEASE PATIENTS

ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN’S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY
ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN’S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY

EARLY ULTRASOUND ASSESSMENT PREDICTS THERAPY RESPONSE: AN EASYTOOL FOR CLINICAL DECISION MAKING
EARLY ULTRASOUND ASSESSMENT PREDICTS THERAPY RESPONSE: AN EASYTOOL FOR CLINICAL DECISION MAKING

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE
SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE

TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN’S DISEASE A MULTICENTER CASE-COHORT STUDY
TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN’S DISEASE A MULTICENTER CASE-COHORT STUDY

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

MATRIX METALLOPROTEINASES GENETIC VARIANTS DETERMINE RISK OF COLON DIVERTICULOSIS
MATRIX METALLOPROTEINASES GENETIC VARIANTS DETERMINE RISK OF COLON DIVERTICULOSIS

MATRIX METALLOPROTEINASES GENETIC VARIANTS DETERMINE RISK OF COLON DIVERTICULOSIS
MATRIX METALLOPROTEINASES GENETIC VARIANTS DETERMINE RISK OF COLON DIVERTICULOSIS

Investigator studies in IBD II (Posters)  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Investigator studies in IBD II (Posters)  et al.

DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS
DEVELOPMENT AND VALIDATION OF A REMOTE MONITORING TOOL FOR REAL-WORLD ASSESSMENT OF MILD, MODERATE, AND SEVERE INFECTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS

Investigator studies in IBD II (Posters)  et al.

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Investigator studies in IBD II (Posters)  et al.

TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN’S DISEASE A MULTICENTER CASE-COHORT STUDY
TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN’S DISEASE A MULTICENTER CASE-COHORT STUDY

Investigator studies in IBD II (Posters)  et al.

SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE
SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE

Investigator studies in IBD II (Posters)  et al.

SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY
SUPERIOR EFFECTIVENESS OF TOFACITINIB COMPARED TO VEDOLIZUMAB IN ANTI-TNF EXPERIENCED ULCERATIVE COLITIS PATIENTS: A NATIONWIDE DUTCH REGISTRY STUDY

Investigator studies in IBD II (Posters)  et al.

EARLY ULTRASOUND ASSESSMENT PREDICTS THERAPY RESPONSE: AN EASYTOOL FOR CLINICAL DECISION MAKING
EARLY ULTRASOUND ASSESSMENT PREDICTS THERAPY RESPONSE: AN EASYTOOL FOR CLINICAL DECISION MAKING

Investigator studies in IBD II (Posters)  et al.

ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN’S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY
ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN’S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY

Investigator studies in IBD II (Posters)  et al.

EARLY ANTI-TNF RESULTS IN HIGHER SUSTAINED STEROID FREE REMISSION RATES IN NEWLY DIAGNOSED PAEDIATRIC CROHN’S DISEASE PATIENTS
EARLY ANTI-TNF RESULTS IN HIGHER SUSTAINED STEROID FREE REMISSION RATES IN NEWLY DIAGNOSED PAEDIATRIC CROHN’S DISEASE PATIENTS

Investigator studies in IBD II (Posters)  et al.

Item 1 - 20 / 20
1